Drug Patent Law Professors Urge Against Exempting Drugs From IPR

Congress should not change the process that the Patent and Trademark Office uses to review patent challenges to drugs and biopharmaceuticals, professors at Duke Law and New York Law School tell Senate Judiciary Committee members. The professors wrote a letter to the committee in response to reports that hedge funds are abusing the inter partes review process at PTO, which the Biotechnology Industry Organization is trying to counter by asking lawmakers to exempt drugs and biopharmaceuticals from IPR challenges. "Overall,...